FDA, Kaiser Discussing COX-2 Myocardial Infarction Study
Executive Summary
FDA may use the Kaiser database to help assess the cardiovascular risk profile of COX-2 inhibitors
You may also be interested in...
FDA Adverse Event Active Surveillance Extends Into Emergency Rooms
FDA has expanded its adverse drug event active surveillance program into 65 emergency rooms nationwide
FDA Adverse Event Active Surveillance Extends Into Emergency Rooms
FDA has expanded its adverse drug event active surveillance program into 65 emergency rooms nationwide
COX-2 Retrospective Study Prompts Review By FDA, Kaiser On Merck’s Vioxx
A retrospective study conducted on COX-2s and NSAIDs has prompted reviews by FDA and Kaiser Permanente on the use of Merck's Vioxx (rofecoxib)